1. Home
  2. KREF vs CABA Comparison

KREF vs CABA Comparison

Compare KREF & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KKR Real Estate Finance Trust Inc.

KREF

KKR Real Estate Finance Trust Inc.

HOLD

Current Price

$7.26

Market Cap

416.7M

Sector

Real Estate

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.80

Market Cap

495.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KREF
CABA
Founded
2014
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
416.7M
495.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
KREF
CABA
Price
$7.26
$2.80
Analyst Decision
Hold
Strong Buy
Analyst Count
6
6
Target Price
$7.88
$14.50
AVG Volume (30 Days)
965.0K
6.7M
Earning Date
04-22-2026
05-14-2026
Dividend Yield
6.49%
N/A
EPS Growth
N/A
10.26
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$545.92
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.25
$1.26
52 Week High
$9.98
$4.23

Technical Indicators

Market Signals
Indicator
KREF
CABA
Relative Strength Index (RSI) 53.33 43.08
Support Level $6.74 $2.77
Resistance Level $7.45 $3.40
Average True Range (ATR) 0.20 0.23
MACD 0.01 -0.02
Stochastic Oscillator 54.27 31.00

Price Performance

Historical Comparison
KREF
CABA

About KREF KKR Real Estate Finance Trust Inc.

KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Share on Social Networks: